Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors

被引：0

作者：

E. Claire Dees

Jeffrey R. Infante

Roger B. Cohen

Bert H. O’Neil

Suzanne Jones

Margaret von Mehren

Hadi Danaee

Yih Lee

Jeffrey Ecsedy

Mark Manfredi

Katherine Galvin

Bradley Stringer

Hua Liu

Omar Eton

Howard Fingert

Howard Burris

机构：

[1] University of North Carolina,UNC Lineberger Comprehensive Cancer Center

[2] Sarah Cannon Research Institute,undefined

[3] Fox Chase Cancer Center,undefined

[4] Millennium Pharmaceuticals,undefined

[5] Inc.,undefined

[6] Forest Research Institute,undefined

[7] Inc.,undefined

[8] Boston University School of Medicine,undefined

来源：

Cancer Chemotherapy and Pharmacology | 2011年 / 67卷

关键词：

MLN8054; Aurora A kinase; Dose-limiting toxicity; Pharmacokinetics; Pharmacodynamics;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：945 / 954

页数：9

共 50 条

[1] Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors
Dees, E. Claire
Infante, Jeffrey R.
Cohen, Roger B.
O'Neil, Bert H.
Jones, Suzanne
von Mehren, Margaret
Danaee, Hadi
Lee, Yih
Ecsedy, Jeffrey
Manfredi, Mark
Galvin, Katherine
Stringer, Bradley
Liu, Hua
Eton, Omar
Fingert, Howard
Burris, Howard
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 67 (04) : 945 - 954
[2] Phase I Study of the Selective Aurora A Kinase Inhibitor MLN8054 in Patients with Advanced Solid Tumors: Safety, Pharmacokinetics, and Pharmacodynamics
Macarulla, Teresa
Cervantes, Andres
Elez, Elena
Rodriguez-Braun, Edith
Baselga, Jose
Rosello, Susana
Sala, Gemma
Blasco, Inma
Danaee, Hadi
Lee, Yih
Ecsedy, Jeffrey
Shinde, Vaishali
Chakravarty, Arijit
Bowman, Douglas
Liu, Hua
Eton, Omar
Fingert, Howard
Tabernero, Josep
MOLECULAR CANCER THERAPEUTICS, 2010, 9 (10) : 2844 - 2852
[3] Phase I and pharmacokinetic study of MLN8054, a selective inhibitor of Aurora A kinase
Dees, E.
Infante, J. R.
Cohen, R. B.
O'Neil, B.
Burris, H.
von Mehren, M.
Gray, G.
Galvin, K.
Manfredi, M.
Eton, O.
EJC SUPPLEMENTS, 2008, 6 (12): : 91 - 91
[4] Phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of the selective aurora A kinase (AAK) inhibitor MLN8054 in patients (pts) with advanced solid tumors
Macarulla, T.
Rodriguez-Braun, E.
Tabernero, J.
Rosello, S.
Baselga, J.
Lee, Y.
Manfredi, M.
Liu, H.
Fingert, H.
Cervantes, A.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[5] Phase I clinical trial of MLN8054, a selective inhibitor of Aurora A kinase
Jones, S. F.
Cohen, R. B.
Dees, E. C.
Lee, Y.
Papas, J. A.
Cooper, M. R.
Galvin, K. M.
Burris, H. A., III
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
[6] MLN8054, a selective inhibitor of Aurora A kinase: final results of a phase I clinical trial
Cervantes, A.
Macarulla, T.
Rosello, S.
Rodriguez-Braun, E.
Baselga, J.
Tabernero, J.
Liu, H.
Chakravarty, A.
Bowman, D.
Eton, O.
EJC SUPPLEMENTS, 2008, 6 (12): : 90 - 90
[7] Dosing strategies for MLN8054, a selective Aurora A kinase inhibitor, based on pharmacokinetic modeling and simulations
Lee, Y.
Eton, O.
Pappas, J.
Chen, S.
Paton, M.
Dees, E. C.
Jones, S.
Cohen, R. B.
Cervantes, A.
Tabernero, J.
EJC SUPPLEMENTS, 2008, 6 (12): : 130 - 131
[8] Preclinical antitumor activity with MLN8054, a small molecule Aurora A kinase inhibitor
Huck, Jessica
Zhang, Mengkun
Burenkova, Olga
Connolly, Kelly
Manfredi, Mark
Meetze, Kristan
CANCER RESEARCH, 2006, 66 (08)
[9] MLN8054, an orally active Aurora A kinase small molecule inhibitor in phase I clinical trials
Manfredi, Mark
Ecsedy, Jeffrey
Meetze, Kristan
Balani, Suresh
Burenkova, Olga
Chen, Wei
Hoar, Kara
Huck, Jessica
Leroy, Patrick
Sells, Todd
Stroud, Steve
Vos, Tricia
Weatherhead, Gabriel
Wysong, Deborah
Zhang, Mengkun
Claiborne, Christopher
CANCER RESEARCH, 2006, 66 (08)
[10] MLN8054: A selective, oral small molecule inhibitor of Aurora A kinase entering clinical development for cancer.
Manfredi, MG
Claiborne, CF
CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9082S - 9082S

← 1 2 3 4 5 →